End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal-Reference-Cited by-同舟云学术

End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal

Published:2007-08-20 Issue:24 Volume:25 Page:3572-3575
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Allegra Carmen¹,Blanke Charles²,Buyse Marc³,Goldberg Richard⁴,Grothey Axel⁵,Meropol Neal J.⁶,Saltz Leonard⁷,Venook Alan⁸,Yothers Greg⁹,Sargent Daniel⁵

Affiliation:

1. University of Florida, Gainsville, FL

2. Oregon Health and Science University, Portland, OR

3. International Drug Development Institute, Louvain-La-Neuve, Belgium

4. University of North Carolina, Chapel Hill, NC

5. Mayo Clinic, Rochester, MN

6. Fox Chase Cancer Center, Philadelphia, PA

7. Memorial Sloan-Kettering Cancer Center, New York, NY

8. University of California San Francisco, San Francisco, CA

9. University of Pittsburgh, Pittsburgh, PA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.12.1368

Reference13 articles.

1. Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial

2. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:204s,2007, (suppl; abstr 238)

3. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

4. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

5. Maindrault-Goebel F, Lledo G, Chibaudel L, et al: OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer: A GERCOR study. J Clin Oncol 24:147s,2006, (suppl, abstr 3504)

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity;ESMO Open;2024-08

2. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

3. Perspectives for the clinical application of ctDNA analysis to breast cancer drug therapy;Breast Cancer;2024-04-23

4. Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study;Frontiers in Oncology;2024-02-12

5. Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study;European Journal of Cancer;2022-07